tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael Ulz, 186 are a BUY (67.39%), 85 are a HOLD (30.8%), 5 are a SELL (1.81%).
Analyst Michael Ulz, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 51.56% that have a potential upside of 39.08% achieved within 180 days. Previously, Michael Ulz worked at BAIRD.
Michael Ulz’s has documented 539 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Financial Services, Industrials sectors.
Most recent stock forecast was given on DYN, Dyne Therapeutics at 08-Sep-2026.
Analyst best performing recommendations are on NRIX (NURIX THERAPEUTICS).
The best stock recommendation documented was for AKRO (AKERO THERAPEUTICS) at 12/19/2022. The price target of $40 was fulfilled within 1 day with a profit of $1.22 (3.15%) receiving and performance score of 31.46.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Jul-2017
$205
$22.5 (12.33%)
5 years 4 months 25 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold Since 03-May-2021
$173
$-9.5 (-5.21%)
$156
5 years 4 months 27 days ago
(03-May-2021)
17/29 (58.62%)
$2.73 (1.60%)
650
Hold Since 04-Feb-2021
$190
$7.5 (4.11%)
$190
5 years 5 months 4 days ago
(26-Apr-2021)
11/14 (78.57%)
$23 (13.77%)
420
Buy Since 06-Sep-2019
$175
$-7.5 (-4.11%)
$165
5 years 7 months 26 days ago
(04-Feb-2021)
3/3 (100%)
$19.41 (12.48%)
397
Buy Since 17-Jul-2017
$166
$-16.5 (-9.04%)
$175
5 years 7 months 26 days ago
(04-Feb-2021)
32/33 (96.97%)
$10.41 (6.69%)
867
Which stock is Michael Ulz most bullish on?
Which stock is Michael Ulz most reserved on?
What Year was the first public recommendation made by Michael Ulz?
